Latest News

The American Association for Cancer Researcher (AACR) named David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and of Medicine (Medical Oncology), as recipient of the 2026 James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research.

Members of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center attended the 48th annual San Antonio Breast Cancer Symposium (SABCS), from December 9-12, 2025.

At SABCS, Yale Cancer Center experts will present groundbreaking research on hormone replacement therapy in breast cancer care, innovative treatment options for HER2-positive and hormone receptor-positive breast cancers, and the impact of patient-centered approaches to care.

Yale School of Medicine faculty members were recognized for publishing studies that rank in the top 1% based on the number of citations they received in their field.

Researchers, led by Thazin Nwe Aung, PhD, in the laboratory of David Rimm, MD, PhD, have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with the most common form of lung cancer to receive more effective individualized treatment.

Regarding finding the right drug for the right patient, the reality of cancer management is far more complex than a single genetic mutation, according to David Rimm, MD, PhD.

It may be time for precision medicine to expand beyond the genomics realm and enter the protein space in the management of melanoma and other cancers, according to David Rimm, MD, PhD.

Dr. David Rimm spoke with Cancer Network on his latest research.

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and professor of medicine at Yale School of Medicine, discussed two important developments to come out of his lab.